IP Library Granted Patent US 7,588,897
Granted Patent B2
US 7,588,897 · App. 11/747,314 · Granted Sep 15, 2009

Compositions and methods to detect

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,588,897
App. No.
11/747,314
Granted
Sep 15, 2009
Kind
B2
Abstract

The disclosed invention includes nucleic acid oligomers that may be used as amplification oligomers, including primers, capture probes for sample preparation, and detection probes for detection of indicator enterococci 23S rRNA sequences in samples by using methods of specific nucleic acid amplification and detection.

Claims (22)

1. A method for amplifying and detecting indicator enterococci nucleic acid in a sample, wherein said indicator enterococci nucleic acid is nucleic acid from E. faecalis, E. faecium, E. casseliflavus, E. gallinarum, E. mundtii, E. durans, E. hirae and/or E. columbae and not from E. avium, E. malodoratus, E. pseudoavium, E. raffinosus, E. saccharolyticus or E. dispar , comprising the steps of:

a) contacting said sample with a first amplification oligomer comprising a target binding region consisting of SEQ ID NO: 30, a second amplification oligomer comprising a target binding region consisting of SEQ ID NO: 31, and a detection probe oligomer comprising a target binding region consisting of SEQ ID NO: 45;

b) exposing said sample to conditions sufficient to amplify indicator enterococci nucleic acid if present in said sample with said first and second amplification oligomers to produce an amplified product; and

c) determining whether said indicator enterococci nucleic acid is in said sample by using said detection probe oligomer to detect the presence or absence of the amplified product.

2. The method of claim 1 , wherein said detection probe oligomer comprises at least one non-target binding region.

3. The method of claim 2 , wherein said detection probe oligomer comprises two non-target binding regions tat hybridize to each other when said detection probe oligomer is not hybridized to indicator enterococci nucleic acid.

4. The method of claim 1 , 2 or 3 , wherein said detection probe oligomer comprises a detectable label.

5. The method of claim 4 , wherein said detection probe oligomer comprises a fluprophore and a quencher.

6. The method of claim 1 , wherein said second amplification oligomer comprises a promoter sequence.

7. The method of claim 6 , wherein said promoter sequence consists of SEQ ID NO: 49.

8. A kit for amplifying and detecting indicator enterococci nucleic acid in a sample, wherein said indicator enterococci nucleic acid is nucleic acid from E. faecalis, E. faecium, E. casseliflavus, E. gallinarum, E. mundtii, E. durans, E. hirae and/or E. columbae and not from E. avium, E. malodoratus, E. pseudoavium, E. raffinosus, E. saccharolvticus or E. disbar , comprising:

a first amplification oligomer 27-100 nucleotides in length comprising a target binding region consisting of SEQ ID NO: 30; a second amplification oligomer 34-100 nucleotides in length comprising a target binding region consisting of SEQ ID NO: 31; and a detection probe oligomer 15-100 nucleotides in length comprising a target binding region consisting of SEQ ID NO: 45.

9. The kit of claim 8 , wherein said detection probe oligomer 15-100 nucleotides in length comprises at least one non-target binding region.

10. The kit of claim 9 , wherein said detection probe oligomer 15-100 nucleotides in length comprises two non-target binding regions that hybridize to each other when said detection probe oligomer is not hybridized to indicator enterococci nucleic acid.

11. The kit of claim 8 , 9 or 10 , wherein said detection probe oligomer 15-100 nucleotides in length comprises a detectable label.

12. The kit of claim 11 , wherein said detection probe oligomer 15-100 nucleotides in length comprises a fluorophore and a quencher.

13. The kit of claim 8 , wherein said second amplification oligomer 34-100 nucleotides in length comprises a promoter sequence.

14. The kit of claim 13 , wherein said promoter sequence consists of SEQ ID NO: 49.

15. The kit of claim 8 , further comprising a capture oligomer.

16. The kit of claim 15 , wherein said capture oligomer comprises SEQ ID NO: 50, 51 or 52.

17. The method of claim 1 , wherein the sample is an enviromnental sample or a biological sample.

18. The method of claim 1 , wherein the sample is a processed sample.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2008
From: POLLNER, REINHOLD B.; LIVEZEY, KRISTIN W.
To: GEN-PROBE INCORPORATED
Reel/Frame 020602/0290 →